TRAF6

Across TCGA pan-cancer cohorts, TRAF6 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated TRAF6 data layer compared with 25 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher TRAF6 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated TRAF6 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and GBM show a favorable association.

PDAC, UCEC, and CCRCC are the cancer types where TRAF6 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Median	All	0.388	0.590	.006	13	view →
UCEC	OS	Median	III,IV	0.315	0.915	.031	4	view →
CCRCC	DFS	Tertile	II,III,IV	0.915	0.399	.040	3	view →
GBM	OS	Median	All	0.932	0.779	.024	1	view →
LUAD	OS	Median	II,III,IV	0.894	0.968	.046	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

TRAF6–PDAC (OS)

Open the PDAC breakdown →